FDA cleared 7.2 mg Wegovy; 20.7% mean weight loss in trial

The FDA cleared a higher dose of Wegovy last month. The nerve pain is the real story.

Novo Nordisk won approval for a 7.2-milligram version of semaglutide on March 19, 2026, and launched it nationally this week with a 20.7 percent mean weight loss figure as the centerpiece. That number — from the STEP UP trial of 1,407 adults with obesity — beats the 17.5 percent shown by the standard 2.4-milligram dose. One in three patients on the new dose lost at least a quarter of their body weight. Novo called it a major clinical advance.

Buried in the same trial data is a different number: 22 percent of patients on the 7.2-milligram dose reported dysesthesia — altered skin sensation, often described as burning, tingling, or electric shocks. That compares to 6 percent on the older dose and 0.3 percent on placebo, according to the PRNewswire release. It is the largest gap in adverse events between the two doses. Dysesthesia is a known class effect for GLP-1 agonists, but the magnitude of the difference at this dose is a signal that physicians and patients need to weigh explicitly — not discover after the fact.

The competitive context makes the triumphalism harder to sustain. Novo launched a discounted subscription plan for self-pay patients in March, weeks before the 7.2-milligram dose was even approved. Reuters reported the move as an effort to regain ground ceded to Eli Lilly's Zepbound. That is not the behavior of a company that just secured a decisive clinical edge. It is the behavior of a company running to stay in place.

Is 20.7 percent a clinical milestone or a marketing threshold? Both can be true. For patients who did not respond adequately to the standard dose, a meaningful increment in weight loss can be genuinely life-changing. Obesity medicine clinicians note that partial responders to GLP-1 therapy often have different outcomes depending on maximum tolerated dose, and a higher-strength option fills a real gap in the treatment ladder.

But the subscription pricing — $399 per month cash, $25 for commercially insured patients — suggests Novo is more focused on patient capture than patient outcomes. Launching a discount program before your new dose has regulatory clearance is not confidence in your product. It is panic dressed up as strategy.

The dysesthesia question deserves more scrutiny than it is getting. Whether the elevated rate is a dose-dependent pharmacological effect, a manifestation of the same gastrointestinal signaling that makes GLP-1 drugs work, or something that clusters in specific patient subgroups is not settled by this trial. What is settled: 22 percent is not trivial, and patients deserve to know before they start.

Wegovy HD (7.2 mg) is available now at more than 70,000 U.S. pharmacies, assembled at Novo's facility in Clayton, North Carolina.